Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)

Trial Profile

A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanabecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly and Company; Eli Lilly Japan
  • Most Recent Events

    • 20 Jul 2023 Results comparing BIN1 risk allele rs6733839 with APOE4 on interdependency among AD risk factors and biomarkers by applying Bayesian Network (BN) modeling to data from Lilly AD clinical trials (A05C (n=142, NCT01565382), A05E (n=217, NCT02016560), AZES (n=206, NCT02245737), LLCF (n=229, NCT02791191), and LZAX (n=194, NCT01900665) ), presented at the Alzheimer's Association International Conference 2023.
    • 31 Jul 2021 This trial has been completed in Spain, according to European Clinical Trials Database record.(End date:2018-10-02).
    • 10 Jan 2019 This study has been completed in Poland.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top